ZAP70 interaction with 13 mRNAs as a potential immunotherapeutic target for endometrial cancer

被引:2
|
作者
Zhang, Yuming [1 ]
Lu, Hai'ou [1 ]
Yu, Yuexin [1 ,2 ]
机构
[1] Gen Hosp Northern Theater Command, Dept Reprod Med, Shenyang 110016, Liaoning, Peoples R China
[2] Gen Hosp Northern Theater Command, Dept Reprod Med, 83 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China
关键词
endometrial cancer; T cell; prognosis; immune checkpoint inhibitors; immunotherapy; REGULATORY T-CELLS; EXPRESSION; LYMPHOCYTES; PROFILE; ZAP-70; TUMORS;
D O I
10.3892/ol.2023.13799
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For advanced, refractory endometrial cancer (EC), it is advisable to find effective immunotherapeutic targets. In the present study, genes affecting the immune status of uterine corpus endometrial carcinoma (UCEC) samples within The Cancer Genome Atlas were explored by weighted correlation network analysis and differential gene expression analysis. The protein function and immune correlation of 14 key genes, including & zeta;-chain-associated protein kinase 70 (ZAP70), were analyzed. Based on the expression levels of key genes, the patients with UCEC were divided into two groups using consensus clustering, low expression (group 1) and high expression (group 2). Next, the functions of differentially expressed genes (DEGs) between the two groups were identified using Gene Ontology enrichment analysis, Kyoto Encyclopedia of Genes and Genomes analysis and Gene Set Enrichment Analysis. The immune status of the patients in the two groups was evaluated using immune infiltration score and the expression levels of targets of immune checkpoint inhibitors. The role of ZAP70 in the prognosis of patients with UCEC and the differences in ZAP70 expression between EC tissues and healthy intimal tissues were determined by reverse transcription-quantitative PCR and immunohistochemistry. The present study found strong correlations between key genes, including ZAP70, LCK, FOXP3, TIGIT, CTLA4, ICOS, CD5, IL2RG, PDCD1, TNFRSF4, CD27, CCR7, GZMB, CXCL9. From the enrichment analyses, it was found that the functions of these DEGs were related to T cells. Patients in group 2 had stronger immune infiltration and higher immune checkpoints expression compared with those in group 1. ZAP70 was expressed at higher levels in EC tissues compared with in normal tissues, and may act as a protective factor in EC. In conclusion, ZAP70 interaction with 13 mRNAs may affect the immune status of patients with EC and may be a potential target for immunotherapy.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer
    Sadras, Teresa
    Martin, Mickael
    Kume, Kohei
    Robinson, Mark E.
    Saravanakumar, Supraja
    Lenz, Gal
    Chen, Zhengshan
    Song, Joo Y.
    Siddiqi, Tanya
    Oksa, Laura
    Knapp, Anne Marie
    Cutler, Jevon
    Cosgun, Kadriye Nehir
    Klemm, Lars
    Ecker, Veronika
    Winchester, Janet
    Ghergus, Dana
    Soulas-Sprauel, Pauline
    Kiefer, Friedemann
    Heisterkamp, Nora
    Pandey, Akhilesh
    Ngo, Vu
    Wang, Lili
    Jumaa, Hassan
    Buchner, Maike
    Ruland, Jurgen
    Chan, Wing-Chung
    Meffre, Eric
    Martin, Thierry
    Muschen, Markus
    MOLECULAR CELL, 2021, 81 (10) : 2094 - +
  • [2] Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer
    Yu, Jianpeng
    Gao, Wenlong
    Gao, Shen
    Wen, Simeng
    Zhao, Yang
    Shang, Zhiqun
    Wang, Yong
    Niu, Yuanjie
    WORLD JOURNAL OF UROLOGY, 2022, 40 (11) : 2817 - 2824
  • [3] Identification of LAT/ZAP70 characterized immune subtypes of prostate cancer
    Jianpeng Yu
    Wenlong Gao
    Shen Gao
    Simeng Wen
    Yang Zhao
    Zhiqun Shang
    Yong Wang
    Yuanjie Niu
    World Journal of Urology, 2022, 40 : 2817 - 2824
  • [4] STING signaling is a potential immunotherapeutic target in colorectal cancer
    ChonL, Hong Jae
    Kim, Hyojoong
    Noh, Jung Hyun
    Yang, Hannah
    Lee, Won Suk
    Kong, So Jung
    Lee, Seung Jun
    Lee, Yu Seong
    Kim, Woo Ram
    Kim, Joo Hang
    Kim, Gwangil
    Kim, Chan
    JOURNAL OF CANCER, 2019, 10 (20): : 4932 - 4938
  • [5] Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
    Jacobs, Julie
    Zwaenepoel, Karen
    Rolfo, Christian
    Van den Bossche, Jolien
    Deben, Christophe
    Silence, Karen
    Hermans, Christophe
    Smits, Evelien
    Van Schil, Paul
    Lardon, Filip
    Deschoolmeester, Vanessa
    Pauwels, Patrick
    ONCOTARGET, 2015, 6 (15) : 13462 - 13475
  • [6] PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall
    Coppock, Joseph D.
    Gradecki, Sarah E.
    Mills, Anne M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2023, 42 (01) : 35 - 42
  • [7] AQP9 and ZAP70 as immune-related prognostic biomarkers suppress proliferation, migration and invasion of laryngeal cancer cells
    Ren, Li
    Li, Ping
    Li, Zhouping
    Chen, Quan
    BMC CANCER, 2022, 22 (01)
  • [8] Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA
    Stamatopoulos, Basile
    Haibe-Kains, Benjamin
    Equeter, Carole
    Meuleman, Nathalie
    Soree, Anne
    De Bruyn, Cecile
    Hanosset, Delphine
    Bron, Dominique
    Martiat, Philippe
    Lagneaux, Laurence
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (06): : 790 - 799
  • [9] Pan-cancer analysis of BRK1 as a potential immunotherapeutic target
    Wang, Xuefeng
    Tang, Yanru
    Liu, Rui
    Li, Wentao
    Liu, Shiyue
    Zhou, Xinhong
    BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, 2024, 40 (03) : 1591 - 1613
  • [10] Androgen receptor as potential therapeutic target in metastatic endometrial cancer
    Tangen, Ingvild Loberg
    Onyango, Therese Bredholt
    Kopperud, Reidun
    Berg, Anna
    Halle, Mari K.
    Oyan, Anne M.
    Werner, Henrica M. J.
    Trovik, Jone
    Kalland, Karl Henning
    Salvesen, Helga B.
    Krakstad, Camilla
    ONCOTARGET, 2016, 7 (31) : 49289 - 49298